Top Banner
1 Pregnancy and MDR-TB Session 7
25

Pregnancy and MDR-TB

Feb 23, 2016

Download

Documents

Bui Nguyet

Pregnancy and MDR-TB. Session 7. Tuberculosis infection during pregnancy. TB disease occurs in a small but definite percentage of pregnant woman. Relative immuno -compromise may allow latent infection to progress to active TB disease. - PowerPoint PPT Presentation
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Pregnancy and MDR-TB

1

Pregnancy and MDR-TBSession 7

Page 2: Pregnancy and MDR-TB

USAID TB CARE II PROJECT

Tuberculosis infection during pregnancy

• TB disease occurs in a small but definite percentage of pregnant woman.

• Relative immuno-compromise may allow latent infection to progress to active TB disease.

• Pregnant women with active TB have a higher risk of complications (pre-eclampsia, vaginal hemorrhage and fetal loss).

Page 3: Pregnancy and MDR-TB

USAID TB CARE II PROJECT

Options for treatment of TB during pregnancy

• Need to consider risks and benefits for the mother and fetus.– Option 1: Stop or delay MDR-TB treatment

• Can be considered if TB disease is not an immediate threat to the health of the patient or if TB is diagnosed in the late stages of pregnancy.

– Option 2: Terminate the pregnancy• May be considered in cases that require injectable agents for

cure.– Option 3: Continue treatment while pregnant

• Treatment is challenging but not contraindicated.• There is minimal data about the safety of second-line anti-

tuberculous agents during pregnancy.

Page 4: Pregnancy and MDR-TB

USAID TB CARE II PROJECT

Pregnancy and MDR-TBRetrospective review of 3089 patients started on MDR-TB treatment from July 1996 to December 2005 in Peru:

– 1033 (33.4%) of these patients were women of child‐bearing age (age, 15–45 years);

– 38 (3.6%) were reported to be pregnant while receiving treatment for MDR‐TB;

– 14 women experienced no changes in their treatment regimen during pregnancy;

– MDR‐TB treatment was suspended after determination of pregnancy for 14 (36.8%) women; and

– 13 women (34.2%) subsequently resumed treatment after discussion with a physician a median of 1.9 weeks (IQR, 1.0–4.6 weeks) after suspension of treatment.

Palacios E, Dallman R, Muñoz M, et al. Drug-resistant tuberculosis and pregnancy: treatment outcomes of 38 cases in Lima, Peru. Clin Infect Dis 2009;48(10):1413-9.

Page 5: Pregnancy and MDR-TB

USAID TB CARE II PROJECT

Treatment outcomes

Treatment outcome Healthy Dead In treatment Unknown Total

(%)

Cure 21 2 23 (60.5)

Death 5 5 (13.2)

Default 3 2 5 (13.2)

Failure 1 1 2 (5.3)

In treatment 2 2 (5.3)

Not known 1 1 (2.6)

Total (%) 24 (63.2) 8 (21.1) 3 (7.9) 3 (7.9) 38 (100.0)

Palacios E, Dallman R, Muñoz M, et al. Drug-resistant tuberculosis and pregnancy: treatment outcomes of 38 cases in Lima, Peru. Clin Infect Dis 2009;48(10):1413-9.

Page 6: Pregnancy and MDR-TB

USAID TB CARE II PROJECT

Children

• Follow‐up data were available for 26/38 children.– 2 children were treated for latent TB (IPT per NTP protocol); – 1 child was treated successfully for active MDR-TB at 19

months of age based on the DST of the mother; – 1 child died of pneumonia shortly after birth (no TB

involvement was reported);– 25 children are currently healthy, including those who were

treated for latent or active TB; and – 2 children have minor health problems:

• 1 child was born with testicular malformation (unlikely to be related to exposure to second-line TB drugs in utero;

• 1 child has idiopathic growth retardation but has otherwise remained healthy.

Palacios E, Dallman R, Muñoz M, et al. Drug-resistant tuberculosis and pregnancy: treatment outcomes of 38 cases in Lima, Peru. Clin Infect Dis 2009;48(10):1413-9.

Page 7: Pregnancy and MDR-TB

USAID TB CARE II PROJECT

Timing of Treatment Initiation

• Ideally avoid treatment during the first trimester. – If the clinical state is severe enough to pose a threat to the life

of the patient, consider treatment during the first trimester.• Start treatment during the second or third

trimester so that the patient will be smear and culture negative at the time of giving birth.

Page 8: Pregnancy and MDR-TB

USAID TB CARE II PROJECT

Safety Classification of Medications During Pregnancy

• A = safety established in human studies.• B = safety presumed based on animal studies.• C = safety uncertain; no human or animal studies

reveal an adverse effect.• D = safety uncertain; evidence of risk but use is

justified in certain circumstances.

Page 9: Pregnancy and MDR-TB

USAID TB CARE II PROJECT

Isoniazid

• Safety class C• Experience with patients suggests safety• Pyridoxine (vitamin B6) should be used during

pregnancy

Page 10: Pregnancy and MDR-TB

USAID TB CARE II PROJECT

Rifampicin

• Safety class C• Experience with patients suggests safety

Page 11: Pregnancy and MDR-TB

USAID TB CARE II PROJECT

Ethambutol

• Safety class B• Experience with pregnant patients suggests safety

Page 12: Pregnancy and MDR-TB

USAID TB CARE II PROJECT

Pyrazinamide

• Safety class C• Formal studies are limited but there is much

clinical experience

Page 13: Pregnancy and MDR-TB

USAID TB CARE II PROJECT

Streptomycin

• Safety class D– Documented toxicity to the developing fetal ear (8-11%).

Toxicity is higher in the first trimester. • Risks and benefits should be carefully considered. • Use should be limited to severe cases when

clinical status and drug resistance warrants use.

Page 14: Pregnancy and MDR-TB

USAID TB CARE II PROJECT

Kanamycin, Amikacin

• Safety class D– Documented fetal ototoxicity – With use of KM, 2.3%

• Risks and benefits should be carefully considered.

Page 15: Pregnancy and MDR-TB

USAID TB CARE II PROJECT

Capreomycin

• Safety class C– Less ototoxicity in adults compared with the aminoglycosides.

• If the risk of morbidity or mortality from TB during pregnancy is high, it is preferable to use CM in place of an aminoglycoside.

Page 16: Pregnancy and MDR-TB

USAID TB CARE II PROJECT

Fluoroquinolones

• Safety class C– No documented teratogenic effects in human studies. Mean

duration given 2-4 weeks.– In 240 pregnant patients, no congenital effects observed.

• Data regarding the prolonged use in pregnant patients is limited, but benefits likely outweigh risks.

Page 17: Pregnancy and MDR-TB

USAID TB CARE II PROJECT

Ethionamide

• Safety class C– Animal studies (high doses);– 2 studies of 47 cases and 1 of 70 cases without adverse

effects;– In another study, 7 of 23 children had congenital

malformations. • The use is controversial given the mixed data; if

an adequate regimen cannot be constructed without it, the use of ethionamide is justified.

• Given its gastrointestinal side effects, nausea and vomiting during pregnancy may be aggravated.

Page 18: Pregnancy and MDR-TB

USAID TB CARE II PROJECT

Cycloserine

• Safety class C– Few studies in pregnant patients – Animal studies do not document toxicity

Page 19: Pregnancy and MDR-TB

USAID TB CARE II PROJECT

PAS

• Safety class C• No data to show teratogenicity

Page 20: Pregnancy and MDR-TB

USAID TB CARE II PROJECT

Breastfeeding

• First-line medications have a variable concentration in breast milk.

• Injectables not absorbed by infant (minimal possibility of toxicity for breastfeeding infant).

• Effects of other medications during breastfeeding unknown.

• Advise mother that breastfeeding is not prohibited but she should consider the risks and benefits of the decision.

Page 21: Pregnancy and MDR-TB

USAID TB CARE II PROJECT

Family Planning

• Of 38 Peruvian women who received MDR-TB therapy while pregnant: – 3 patients (7.9%) were pregnant at the initiation of MDR‐TB

therapy and had been pregnant for a median of 8.2 months (IQR, 7.3–8.2 months).

– 35 patients (92.1%) became pregnant while receiving treatment; these patients became pregnant a median of 9.7 months (IQR, 4.4–17.0 months) after treatment initiation.

Palacios E, Dallman R, Muñoz M, et al. Drug-resistant tuberculosis and pregnancy: treatment outcomes of 38 cases in Lima, Peru. Clin Infect Dis 2009;48(10):1413-9.

Page 22: Pregnancy and MDR-TB

USAID TB CARE II PROJECT

Recommendations

• The best way to deal with MDR-TB and pregnancy is to prevent it.

• All women of child-bearing age should be offered a reliable method of family planning by the health care worker providing MDR-TB treatment (integrated family planning). – A “reliable method” excludes abstinence and condoms. – Depo-Provera can be provided at 3 month intervals during the

clinic visit.

Page 23: Pregnancy and MDR-TB

USAID TB CARE II PROJECT

Recommendations

• Provide individualized care based on risks and benefits to the patient and fetus.

• The patient should be involved in therapeutic decisions.

• If pregnancy occurs during treatment and the patient is stable, treatment can be deferred until the second trimester unless there is clinical deterioration.

Page 24: Pregnancy and MDR-TB

USAID TB CARE II PROJECT

Recommendations

• During the first 20 weeks of pregnancy, avoid the injectable if possible.– Exception: if the risk of morbidity or mortality is high, an

injectable agent should be used (preferably CM). • There is limited evidence, but clinical experience

has shown that cycloserine, fluoroquinolones, and PAS may be used in pregnant patients.

Page 25: Pregnancy and MDR-TB

USAID TB CARE II PROJECT

Recommendations

• Ethionamide and prothionamide– Some cases of congenital fetal defects;– Not enough data to confirm the safety or risks of these

medications.• Use pyridoxine (vitamin B6) in all pregnant

patients.• Breastfeeding is permissible, however the risks

and benefit should be discussed with the patient.